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ABSTRACT 
The ageing of society is undoubtedly a success, but also a challenge of modern medicine. Postmenopausal 
women struggle with many health problems, and their treatment recommended so far is often associated 
with many side effects such as the increased risk of hormone-dependent tumours or thromboembolism. The 
purpose of this article is to discuss the effects of a relatively new drug called tibolone against the currently 
recommended treatment. The unique mechanism of estrogenic, progestogenic, and androgenic action 
of tibolone is due to the breakdown of the parent compound into 3 active metabolites, each selectively 
acting on different tissues differently. Tibolone is approved for the relief of menopausal symptoms and its 
effectiveness is similar to that of hormone replacement therapy and the prevention of osteoporosis. The 
article will also discuss the results of various studies on the risk of cancer during treatment with tibolone, 
especially in comparison to hormone replacement therapy. Tibolone affects also the cardiovascular system, 
including reducing the level of lipoprotein a, total cholesterol, triglycerides, and HDL. Tibolone also has 
a neuroprotective effect and improves mood and libido. Like all medicines, tibolone is not free from side 
effects such as weight gain, vaginal bleeding, hirsutism, and inflammation of the reproductive organs, 
so the benefits and risks of therapy should always be considered. There are still no clear conclusions 
regarding many aspects of the influence of tibolone on the patient’s body, therefore large studies are 
needed to assess the effectiveness and safety of tibolone.
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The ageing of societies is a global phenomenon. 
In 2015, the population of people over 60 years old 
accounted for 12% of the world’s population, and the 
number is increasing every year. It is estimated that 
by 2050 the elderly people will constitute as much as 
21.5% of the population. These changes are particularly 
visible in Europe. The data published by the European 
Commission in 2011 shows that by 2060, approximately 
30% of Europe’s population will be over 65 years old 
[1]. While this is undeniably a sign of medical progress, 
it brings new challenges. In the elderly population, 
multi-morbidity is characteristic [2]. The typical prob-
lems among elderly people include diseases of the 
musculoskeletal system, the cardiovascular system, the 
nervous system, metabolic diseases, weakening of the 
body’s defence systems, hormonal changes, and men-
tal and social problems [1]. Preservation of the physical 
activeness and the quality of life of the elderly, enabling 
their independent functioning requires the coopera-
tion of specialists in various medical and paramedical 
fields. This involves taking multiple medications, that are 
not free from side effects [2]. That is why dynamically 
developing medicine faces the challenge of improving 
these therapies. One of the solutions is to look for new, 
alternative drugs. In this article is presented the appli-
cation of Tibolone, and its place among other drugs 
used to treat the postmenopausal women population. 
About its indications and unique properties, but also the 
dangers and limitations of the use of this drug.
The unique mechanism of action of 
tibolone
Tibolone was synthesized in 1964 by Organon 
Research and Development Laboratories in the Neth-
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erlands, but it took 25 years of research to be finally 
approved for use [3]. It has been widely used in many 
countries for many years but has not been introduced 
in the USA yet [4]. It differs from other drugs by selec-
tive action on different tissues in a different way. This 
synthetic steroid has been classified as a selective 
regulator of estrogenic activity in tissues (STEAR) [3]. 
The reason why tibolone is so unique is that the parent 
compound, structurally similar to norethynodrel and 
virtually no pharmacological activity, is converted in 
the body into 3 active metabolites: 3a-hydroxytibolone, 
3b-hydroxytibolone, and the D4 isomer. Each of these 
compounds has a different effect. 3a-hydroxytibolone 
and 3b-hydroxytibolone are weak oestrogens and bind 
to oestrogen receptors in the vagina, brain, and bone 
with minimal effect on the endometrium. In addition, 
hydroxymetabolites inhibit the action of sulfatase, which 
leads to a decrease in the conversion of oestrogen to 
oestradiol in the breast so that the estrogenic stimulation 
is lower. Whereas the ∆4-isomer shows progestogenic 
activity mainly on the endometrium, which reduces its 
proliferation. D4-isomer also has an androgenic effect 
in the brain and the liver, affecting lipid levels. Regard-
ing the effects on the breasts, the D4 isomer inhibits 
the proliferation of breast tissue and stimulates its 
apoptosis [4].
Tibolone has been approved for the treatment of 
climacteric symptoms and the prevention of osteoporo-
sis occurring in women who are at least one year after 
menopause [5]. It has a positive effect on the mental 
and sexual spheres. Studies also show that tibolone 
prevents endometrial proliferation and vaginal atrophy, 
and also relieves urogenital symptoms. 
The overall tolerance of tibolone is also assessed 
as good [6].
Menopausal symptoms
Every ageing woman experiences physiological 
hormonal changes in her body. Over the years, ovarian 
follicles are lost, and the levels of hormones secreted 
by them decrease. This leads to an increase in FSH 
levels, which is a major feature of the menopausal tran-
sition [7]. Each woman starts menopause individually, 
usually between the ages of 45 and 52 [8]. In addition 
to menstrual disorders, this period is associated with 
the emergence of significant and bothersome clinical 
symptoms, which increase with the duration of the 
menopausal transition. First and foremost, they include 
hot flashes, as well as poor sleep, urogenital atrophy, 
and unfavourable mood [7].
Most women experience vasomotor symptoms, 
i.e., hot flushes and night sweats. They are most pro-
nounced a few years before and immediately after their 
final menstrual period, but a small percentage of women 
will never be free from them. In addition to reducing the 
quality of life, hot flushes can negatively affect health 
because this symptom has been shown to correlate 
with reduced heart rate variability, which is associated 
with a higher risk of cardiovascular disease. About 
a quarter to a third of menopausal women experience 
vaginal symptoms that, unlike hot flashes and sleep 
disturbances, do not go away without treatment [7]. 
They include several troublesome ailments such as 
itching of the vulva, vaginal dryness, vaginal discharge, 
dyspareunia, or dysuria [9].
Studies are suggesting the effectiveness of comple-
mentary and alternative medicine in reducing stress and 
the nuisance of symptoms related to menopause, such 
as cognitive behavioural therapy and phytoestrogens 
[8]. Patients may also be offered paroxetine mesylate 
or clonidine for vasomotor symptoms or a low dose of 
gabapentin at night when hot flushes occur at night, 
ospemifene (a new selective oestrogen receptor mod-
ulator - SERM) for vaginal dryness, and selective sero-
tonin reuptake inhibitors (SSRI) or melatonin receptor 
agonists for other symptoms. However, most often 
women with the typical symptoms of menopause are 
offered hormone therapy [7]. They are effective in com-
bating vasomotor symptoms (they reduce the frequency 
of symptoms by 75% and their intensity by 87%) and 
urogenital atrophy, prevent bone loss, reduce the risk 
of type 2 diabetes and ischemic heart disease, and im-
prove mood and quality of life. Hormone therapy can be 
divided into oestrogen-only therapy (when the woman 
has had a hysterectomy) and oestrogen-progesterone 
therapy (adding a dose of progesterone is necessary 
because oestrogen alone would stimulate endometrial 
cell division) [10]. Vaginal oestrogen therapy is the 
method of choice in the treatment of urogenital atrophy, 
thanks to which complications related to systemic ther-
apy are not observed [9]. It is important to remember 
about the side effects of hormone replacement ther-
apy, such as mastodynia, fluid retention, nausea, leg 
cramps, headache, uterine bleeding, increased risk of 
thromboembolism (it seems that the solution could be 
the percutaneous supply of oestrogen, which poses 
a lower risk of a thromboembolic event) as well as 
depression, anxiety, bloating and increased appetite if 
the progesterone component is also included. And in 
long-term follow-up, they can lead to the development 
of tumours, which will be discussed in more detail later 
in this article [10–12].
Alternative therapy is the administration of tibolone, 
which, due to its unique mechanism of action, also 
works well in alleviating menopausal symptoms, and 
studies comparing oral hormone replacement therapy 
with tibolone shows similar effectiveness. At the same 
time, the incidence of vaginal bleeding and breast ten-
142
MEDICAL RESEARCH JOURNAL 2021. vol. 6. no. 2
www.journals.viamedica.pl/medical_research_journal
derness is lower than with standard HRT [11, 12]. In 
a study comparing transdermal oestrogen (although it 
was performed in a small group of patients), statistically 
better results of transdermal oestrogen than tibolone 
were reported. However, in another study comparing 
the effects of tibolone and transdermal oestrogen in 
surgically menopausal women, tibolone was more 
effective [12].
In conclusion, tibolone should be preferred in 
women who experienced undesirable side effects after 
hormone replacement therapy and who have already 
gone through menopause and are struggling with acute 
menopausal symptoms [10].
Tibolone and cancer risk
Hormone replacement therapy is undoubtedly a risk 
factor for cancer of oestrogen-dependent tissues. Wom-
en taking combined oestrogen-progesterone therapy 
have an increased risk of developing breast cancer, 
while oestrogen-only therapy does not appear to 
increase that risk. On the other hand, the risk of endo-
metrial cancer is increased with oestrogen-only therapy 
and the addition of progesterone reduces it [13]. The 
risk of developing ovarian cancer is increased in both 
oestrogen and oestrogen-progesterone therapy [14]. 
Since many women and their doctors are concerned 
about HRT, another treatment like tibolone could 
be considered.
The tissue-selective D 4-metabolite of tibolone with 
progestogenic properties prevents the proliferation of 
endometrial cells, therefore additional progesterone is 
not required during this therapy. Endometrial atrophy 
has been observed in several years of clinical obser-
vations of the use of tibolone. The safety of tibolone 
therapy was compared to that of continuous oestro-
gen-progesterone therapy with a lower percentage of 
irregular bleeding and spotting from the genital tract. 
In a small study conducted by the Medical University 
of Warsaw, none of the women, during the 12-month 
follow-up, revealed cancer or endometrial adenoplas-
ma. Atrophic changes of the endometrium were found 
and were associated with a low percentage of vaginal 
bleeding. However, there have been some reports in the 
literature of endometrial adenocarcinomas in women 
treated with tibolone [15].
According to a Danish study, postmenopausal 
tibolone substitution is associated with an overall in-
creased risk of ovarian and endometrial cancer. This 
is especially true of serous ovarian tumours and type 
I endometrial cancer. The risk increases with the longer 
duration of therapy [14]. An epidemiological study was 
also carried out in the UK and it was found that women 
treated with tibolone for at least 2 years had a higher 
risk of developing endometrial cancer compared to 
women using hormone replacement therapy, although 
the authors of this study emphasize that tibolone was 
not always prescribed under the license for use in 
women who are at least one year postmenopausal 
or have been prescribed for women with a previous 
history of uterine bleeding. Therefore, more detailed 
research on the relationship between the use of ti-
bolone and the occurrence of endometrial neoplasms 
is necessary [16].
A complication of hormone replacement thera-
py (especially when oestrogen alone) may also be 
the reactivation of endometriosis and stimulation of 
malignant transformation in women with a history of 
endometriosis. Due to the lack of high-quality studies, 
it is not possible to clearly indicate the best treatment 
option for these women. The authors of some studies 
indicate that tibolone may be a safer alternative, but 
there is no clear evidence for it [17].
It is worth remembering that breast cancer is the 
most common malignant neoplasm of women in devel-
oped countries and one of the leading causes of death 
in women over 60 years old [18]. As already mentioned, 
studies have shown that in the breast, tibolone metab-
olites regulate the activity of enzymes that are locally 
involved in the production of oestrogens (the activity of 
which explains why the risk of breast cancer does not 
decrease after menopause) and have antiproliferative 
and proapoptotic effects on cells. Animal studies in rats, 
monkeys and nude mice have shown efficacy in inhibit-
ing the growth of breast tumours (at the level of tamox-
ifen efficacy) and preventing tumour growth. There 
are also studies that in women with a history of breast 
cancer treated with tamoxifen, tibolone was effective 
and safe in relieving menopausal symptoms. Contrary 
to standard HRT, breast tenderness was less frequent 
in women treated with tibolone [19].
However, the Million Women Study conducted in 
the UK found a significant increase in the number of 
breast cancer cases in women using tibolone. Although 
it was much lower than with oestrogen-progesterone 
therapy (leading to an approximately fourfold increase 
in the risk of breast cancer), it was still slightly higher 
than with oestrogen-only therapy [20].
Another side effect of HRT is an increase in the 
density of mammograms, making it difficult to interpret 
this important breast cancer screening test. Tibolone 
does not show this effect. Some studies even report 
a decrease in mammography density after the use of 
tibolone. Although epidemiological studies show an 
increased risk of breast cancer in women treated with 
tibolone, it may be related to the increased detection 
of cancer in radiological tests [19].
Moreover, some clinical studies suggest that ti-
bolone may reduce the risk of colon cancer [3].
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All of this suggests that tibolone may have an ad-
vantage over standard HRT in terms of breast cancer 
risk, but this is not certain enough to make it lose on-
cological alertness.
The effect of tibolone on the 
cardiovascular system
Oestrogen deficiency in postmenopausal women 
is also associated with many changes in the vascular 
system. With age, the blood pressure value and lipid 
profile change, vascular reactivity decreases, glucose 
tolerance is impaired, and thus the cardiovascular risk 
increases. The effectiveness of HRT in reducing car-
diovascular events is so far debatable [21]. A serious 
complication of HRT is a significantly increased risk of 
thromboembolism [10]. Also, clinical and observational 
studies have confirmed that standard HRT doses in-
crease the relative risk of stroke, especially in women 
over 60 years of age [22].
The tibolone discussed in this article has been 
shown to reduce Lp (a), total cholesterol, and tri-
glycerides in clinical trials as well as HDL cholesterol 
levels. High levels of LDL-C, Lp (a) and triglycerides, and 
low levels of HDL-C are associated with an increased 
risk of cardiovascular disease [23]. While it is empha-
sized that Lp (a) is an independent risk factor for car-
diovascular disease and lowering Lp (a) levels may be 
critical in preventing CVD, and changes in HDL-C levels 
are transient, there are no long-term studies to support 
the theory that a decrease in Lp (a) does indeed lead to 
a reduction in cardiovascular events [24]. Moreover, no 
significant difference was found between the effect of 
tibolone and standard HRT on Lp (a) concentration [25].
The fall in oestrogen levels may make hypertension 
more common in menopausal women. Due to the 
occurrence of hypertension in young women taking 
contraceptive pills and inconclusive results of studies 
on the effect of HRT on blood pressure, the influence of 
tibolone in this aspect was discussed. In a randomized 
trial in hypertensive women, no clinically significant 
changes in blood pressure were found between the 
tibolone and placebo-treated groups. The authors con-
sidered tibolone 2.5 mg safe for use in women treated 
or untreated [26]. However, in the study comparing the 
effect of Drospirenone combined with 17b-oestradiol 
(E2) with tibolone, it was concluded that tibolone does 
not show vascular function resulting from estrogenic 
properties, most likely due to additional progesterone 
and androgenic component [21].
Interesting results of the OPAL study also report 
the progression of atherosclerosis, as measured by 
the progression of carotid intima-media thickness, in 
both tibolone and standard HRT therapy compared to 
placebo, which may be associated with an increased 
cardiovascular risk. However, other, smaller studies do 
not confirm this relationship [27].
Other factors that appear to increase the risk of 
cardiovascular disease are increased levels of fibrin-
ogen and low levels of antithrombin III. Despite previ-
ous reports on the profibrinolytic activity of tibolone, 
the meta-analysis of studies does not suggest either 
a significant reduction in fibrinogen concentration or 
changes in plasma ATIII concentration, regardless of 
the duration of treatment with tibolone. The authors of 
this meta-analysis suggest that this form of therapy is 
neutral in terms of the occurrence of thromboembolic 
events [4, 27].
Concerns about the safety of tibolone arose during 
the Fracture Incidence Study in the Elderly Osteoporo-
sis Population (LIFT), which was discontinued due to 
an observed increased risk of stroke [3, 27]. However, 
results from the General Practice Research Database 
indicate that tibolone was not associated with an in-
creased risk of stroke [22]. The differences may be 
because women in the LIFT study had a more severe 
medical history [3].
In conclusion, there is still a lack of conclusive and 
reliable scientific data to determine the overall effect of 
tibolone on cardiovascular morbidity and mortality [26].
Osteoporosis
Four main groups of drugs are used during osteopo-
rosis: bisphosphonates, selective oestrogen modulating 
receptor, parathyroid hormone derivatives and stron-
tium ranelate. The limitations of pharmacotherapy with 
bisphosphonates include gastrointestinal complaints, 
atrial fibrillation or significant impairment of functions, 
i.e., diseases occurring among geriatric patients. Ralox-
ifene - a selective oestrogen receptor modulator - may 
increase vasomotor symptoms and increase symptoms 
of thromboembolism. Parathyroid hormone deriva-
tives have serious ineffectiveness among people with 
kidney failure or hypercalcemia. The use of strontium 
ranelate in concomitant dysfunction of the kidney will 
prove to be inappropriate. The numerous options of 
the above-mentioned drugs encourage the search for 
alternative therapies, which include tibolone [28].
In postmenopausal women, the risk of osteoporosis 
increases significantly due to the decreased synthesis 
of oestrogens, especially 17-b-estradiol [29]. The role 
of these hormones is to inhibit osteoblast apoptosis 
and reduce the viability of osteoclasts due to the inter-
action with cytokines that regulate the death processes 
of these cells [30]. In addition, oestrogens reduce 
calciuria, which also helps to maintain the body’s cal-
cium-phosphate balance [29]. Scientific studies have 
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shown that tibolone, due to the content of oestrogens, 
reduces the risk of vertebral and extra-vertebral oste-
oporotic fractures [31]. An additional advantage is the 
presence of androgens that stimulate the synthesis 
of new bone tissue, which in turn causes a greater 
increase in bone density compared to oestrogen-on-
ly therapy. The anti-resorptive effect of tibolone is 
dose-dependent - 2.5 mg of the drug inhibits resorption 
more effectively than the use of 1.25 mg [30]. It is sug-
gested that the lower dose should be used in asymp-
tomatic patients or as part of maintenance therapy, and 
the higher dose in the presence of severe symptoms of 
menopause [32]. Tibolone turns out to be particularly 
beneficial in women after an osteoporotic fracture or 
with the presence of risk factors for such a fracture, in 
the case of contraindications to the use of denosumab 
and bisphosphonates, as well as in patients with partic-
ularly severe vasomotor symptoms of menopause [33, 
34]. Due to the proven cartilage-protective properties 
of some selective oestrogen receptor modulators, one 
study raised the question of whether such an effect 
would also be observed in the case of tibolone. How-
ever, no such relationship has been demonstrated, 
which may be related to the effect on receptors other 
than oestrogen receptors [35].
Central nervous system
Sex hormones also regulate many processes 
within the central nervous system. There are two types 
of oestrogen receptors in the brain. Within the hypo-
thalamus, the majority are alpha receptors, while beta 
receptors dominate within the structures responsible for 
motor and cognitive functions [30]. In animal studies, 
the stimulating effect of oestrogens on the synapto-
genesis process in the hypothalamus and increasing 
the number of spines of dendritic pyramidal cells in 
the hippocampus has been proven. It is assumed that 
the disappearance of dendritic spines is caused by the 
activity of the GABA-ergic system, which increases with 
oestrogen deficiency. Particularly noteworthy is the fact 
that androgens act antagonistically to GABA receptors 
[36]. Progesterone also stimulates the process of syn-
aptogenesis and myelination [37]. Therefore, tibolone 
has a positive effect on the learning process and 
memory, and in particular, improves semantic memory 
[38]. However, there are reports of an adverse effect 
of tibolone on the performance of activities requiring 
concentration and task planning [39].
It has also been shown that oestrogens influence 
the processes regulating oedema, astrogliosis and the 
inflammatory response following brain damage [40]. 
Their protective effect against astroglia and microglia 
cells under inflammatory conditions was also observed. 
It is worth emphasizing that progesterone also protects 
nerve cells against the influence of factors inducing ox-
idative stress [42]. Interestingly, tibolone regulates the 
phagocytosis of astrocytes more effectively in women 
than in men [42].
When discussing the various implications of tibolone 
pharmacotherapy, one should not forget about the 
increase in the level of neurotransmitters in the cholin-
ergic and serotonergic systems. In addition, the drug 
regulates the phosphorylation of the Tau protein, which 
plays a key role in the pathogenesis of tauopathies such 
as, for example, Alzheimer’s disease. Its neuroprotective 
effect should be considered in the context of its use in 
the treatment of postmenopausal neurodegenerative 
diseases [38].
Mood and cognitive functions 
Neuroendocrine and metabolic changes taking 
place during menopause adversely affect the mental 
sphere of patients - symptoms of depression or anxiety 
often appear [39]. Lowered mood and libido may also 
result indirectly from vasomotor symptoms [43]. After 
the tibolone therapy, an improvement in mood was 
observed, and beneficial effects were also noted in 
women struggling with the problem of chronic fatigue 
or reduced motivation [30].
The positive influence on the mental aspects can 
be explained by several mechanisms. Firstly, scientific 
studies have shown that oestrogens affect serotonergic, 
dopaminergic and adrenergic neurotransmission and 
increase the concentration of beta-endorphins in both 
plasma and pituitary gland [30,39]. It is presumed that 
the increase in the level of androgens positively cor-
relates with the level of beta-endorphins [39]. These 
chemical compounds are endogenous opioids influenc-
ing thermoregulation, behavioural functions and show-
ing analgesic properties [44]. It was also proved that 
tibolone increased their concentration and stimulated 
the synthesis of allopregnanolone - a neurosteroid that 
acts agonistically in relation to the GABAa receptor [39, 
44]. Stimulating the activity of this receptor reduces the 
level of anxiety and has a sedative effect [39].
Sexual functions
In the menopausal period, a frequently reported 
complaint is a decrease in the level of satisfaction 
with sex life [43]. Oestrogen deficiency predisposes 
to the development of atrophic vaginosis and urethral 
syndrome. These diseases are one of the causes of 
dyspareunia, which negatively affects the quality of 
sexual life [30]. In addition, decreased libido may be 
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a result of a decrease in androgen levels, as well as 
a consequence of accompanying mood disorders. Oes-
trogens positively influence the function of nerves in the 
genital system and increase vaginal lubrication [43]. It 
has been shown that tibolone reduces the symptoms 
of atrophic inflammation, stimulates vaginal blood flow 
and stimulates lubrication [30, 45]. Thanks to its affinity 
to androgen receptors and the reduction of SHBG con-
centration in the plasma, it increases the concentration 
of free testosterone, which is responsible for maintaining 
normal libido. As a consequence, patients more often 
undertake sexual contacts and report an increase in 
desire, excitement and satisfaction with intercourse [39].
Other side effects
Side effects in patients taking tibolone not covered 
in the above considerations include abdominal pain, 
weight gain and bloating. Some patients reported vagi-
nal bleeding, breast tenderness, genital pruritus, head-
aches, the hirsutism. [5] Short-term increases in serum 
transaminases were also noted in clinical trials. Several 
cases of liver injury correlating with treatment have been 
reported. Treatment has been identified as causing clin-
ical liver injury, but the mechanism is unknown. So far, 
there have been no cases of acute liver failure, death, 
or chronic hepatitis [46].
Two studies suggest that tibolone may worsen the 
vaginal infection, although neither of them has provided 
an aetiology. One study reports urinary tract infections 
[47]. There was a case of a patient with polycythaemia 
secondary to the use of tibolone [48]. In in vitro studies, 
tibolone induces the proliferation of glioblastoma cells, 
which may be related to its activity at oestrogen and 
progesterone receptors. However, it does not affect 
the migration or invasiveness of neoplastic cells [49].
Conclusions
According to data published by the European Com-
mission, every third adult will be over 65 by the end of 
2060. The progressive ageing of society is not only an 
economic challenge but also a medical one, which 
is why it is so important to focus the scientific devel-
opment on ailments that often occur among geriatric 
patients. This idea led us to discuss drug therapy with 
tibolone. Its uniqueness and the possibility of utilizing 
pleiotropic effects is because, despite being classified 
as a selective regulator of estrogenic activity, it also has 
progestogenic and androgenic effects. Tibolone may 
be used as an alternative therapy in patients who do 
not tolerate conventional hormone replacement thera-
py because it shows similar effectiveness and greater 
effectiveness in reducing breast tenderness or vaginal 
bleeding. The effect on cancer development is uncertain 
– studies describing an increased risk of endometrial 
cancer and a decreased likelihood of developing breast 
cancer compared to HRT are emerging. The effect of 
tibolone on the cardiovascular system remains incon-
clusive - some studies suggest that it accelerates the 
progression of atherosclerosis and is pro-fibrinolytic, but 
other articles present just the opposite conclusions. Ti-
bolone reduces the risk of vertebral and non-vertebral 
fractures, especially in women with a previous fracture 
or with risk factors. Concerning the central nervous sys-
tem, a neuroprotective effect, improvement in semantic 
memory and learning, as well as an unfavourable effect 
in the field of task planning, have been noted. In the 
described studies, tibolone turned out to be effective 
in patients with increased anxiety or decreased mo-
tivation, which most likely results from the increased 
concentration of beta-endorphin in the body. Due to 
the increase in vaginal flow and lubrication, women 
reported an increase in sexual satisfaction. The most 
common side effects include weight gain, headaches 
and abdominal pain, vaginal itching and bleeding, and 
hirsutism. Summarizing this article, the mechanisms 
of action and clinical implications of tibolone are still 
not fully understood. It is necessary to conduct further 
research on this drug, which may significantly affect the 
effectiveness of pharmacotherapy in the population of 
geriatric patients.
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